Traditionally, clinicopathologic characteristics such as tumor size, axillary nodal status, histologic and nuclear grade, hormone receptors [estrogen receptor (ER) and progesterone receptor (PR)], and human epidermal growth factor receptor 2(HER2) status have been used to identify risk groups and to predict patient prognoses (3, 4). Here, ERBB2 is linked to neoplasm.